Previous close | 90.87 |
Open | 91.14 |
Bid | 90.45 x 200 |
Ask | 90.50 x 100 |
Day's range | 90.02 - 91.53 |
52-week range | 76.02 - 99.56 |
Volume | |
Avg. volume | 1,406,075 |
Market cap | 17.169B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 103.99 |
EPS (TTM) | 0.87 |
Earnings date | 24 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 109.70 |
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.